The angiotensin receptor antagonists are the latest addition to the therapeutic arsenal of cardiovascular drug therapy. Over the past few years, several of these exciting compounds have become available to the practicing physician. The book of Epstein and Brunner comprehensively discusses this rapidly emerging new class of drugs.
The editors have assembled an impressive panel of national and international experts and authors.
The book is divided into five different sections. The first three sections deal with mostly experimental and pharmacologic studies providing a solid fundament for clinical experience and ongoing trials with the angiotensin receptor inhibitors, which are covered in the last two sections. Drs Epstein and Brunner are to be commended for the selection of the authors covering the clinical experience. A wealth of useful and lively information is provided to the practicing physician in this section. Particularly important are the chapters on combination therapy, renal protection, and diabetes mellitus. Dr Zanchetti concludes this section by comprehensively reviewing the presently ongoing morbidity and mortality trials with angiotensin antagonists.
What perhaps should be worked out in future editions is the question whether or not there are differences in antihypertensive efficacy among various angiotensin receptor inhibitors, as was suggested by a few very recent studies. The book of Epstein and Brunner is well arranged, covers all aspects of this exciting new drug class, and, therefore, can be recommended to practicing physicians-general internists, nephrologists and cardiologists alike.
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